Medicare Enrolled
Dr. Robert Gianfagna, MD
Cardiovascular Disease · Buffalo, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Gianfagna from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gianfagna?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gianfagna
Dr. Robert Gianfagna is a cardiovascular disease specialist in Buffalo, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Gianfagna performed 2,297 Medicare services across 1,642 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gianfagna received a total of $10,934 from 41 pharmaceutical and/or device companies across 619 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gianfagna is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 41% volume in NY
$10,934 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,297
Medicare services
Top 41% in NY for cardiovascular disease
1,642
Unique beneficiaries
$40
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~121 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| EKG interpretation and report A standard electrocardiogram test that records the heart's electrical activity using at least 12 leads. The service includes a professional interpretation of the results and a written report. |
719 | $5 | $34 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
481 | $82 | $241 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
336 | $9 | $154 |
| Anticoagulant management for warfarin Management of anticoagulant therapy for a patient taking warfarin. This service involves monitoring and adjusting the medication regimen. |
228 | $7 | $22 |
| Regadenoson injection (Lexiscan) for heart stress test An injection of regadenoson, a medication used to stress the heart during diagnostic testing. |
116 | $38 | $74 |
| Echocardiogram, transthoracic An ultrasound of the heart that uses color to show blood flow, rate, direction, and valve function. |
104 | $138 | $655 |
| Technetium Tc-99m sestamibi diagnostic injection A diagnostic injection of technetium Tc-99m sestamibi used for imaging studies. |
57 | $84 | $473 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
40 | $114 | $311 |
| Exercise or drug-induced heart stress test with ECG A heart stress test performed using exercise or medication while monitoring the electrocardiogram under physician supervision and review. |
35 | $45 | $356 |
| Remote monitoring of implantable heart rhythm device Evaluation of data transmitted remotely from an implantable cardiovascular monitor, such as a loop recorder or subcutaneous cardiac rhythm monitor, over a period up to 30 days. |
34 | $54 | $337 |
| Pacemaker programming, dual lead system Adjustment and configuration of a dual-lead pacemaker device to ensure proper operation and settings. |
32 | $46 | $240 |
| Evaluation of implantable heart and blood vessel monitoring system This procedure involves checking the function and data of an implanted device used to monitor heart and blood vessel activity. |
29 | $23 | $167 |
| Nuclear stress test of heart muscle A nuclear medicine imaging test that evaluates blood flow to the heart muscle at rest and during stress using a special camera. |
23 | $324 | $701 |
| Perflutren lipid microspheres injection Injection of perflutren lipid microspheres, measured per milliliter. |
18 | $34 | $202 |
| Remote evaluation of implantable defibrillator system Remote assessment of a single, dual, or multiple lead implantable defibrillator system within 90 days of the previous evaluation. |
17 | $23 | $311 |
| Remote pacemaker/defibrillator monitoring, 90 days Remote evaluation of a pacemaker or implantable defibrillator system within 90 days of the last check. |
17 | $15 | $190 |
| Continuous ECG monitoring, up to 30 days Continuous heart rhythm monitoring for up to 30 days, including professional review and reporting of the results. |
11 | $20 | $68 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
7.4% high complexity
10.8% medium
81.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,934
Total received (2018-2024)
Avg $1,562/year across 7 years
Top 19% in NY for cardiovascular disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
41
Companies
619
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,895 (99.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$38 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,046
2023
$1,612
2022
$1,679
2021
$1,140
2020
$827
2019
$2,513
2018
$2,117
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Actelion Pharmaceuticals US, Inc.
$195
Amgen Inc.
$167
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$96
Boehringer Ingelheim Pharmaceuticals, Inc.
$91
Novartis Pharmaceuticals Corporation
$85
SCPHARMACEUTICALS INC.
$70
E.R. Squibb & Sons, L.L.C.
$55
Edwards Lifesciences Corporation
$50
Novo Nordisk Inc
$49
PFIZER INC.
$48
Impulse Dynamics (USA) Inc.
$27
ABIOMED
$26
Lexicon Pharmaceuticals, Inc.
$18
Merck Sharp & Dohme LLC
$18
Janssen Pharmaceuticals, Inc
$18
AstraZeneca Pharmaceuticals LP
$16
Boston Scientific Corporation
$16
Top 3 companies account for 43.9% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$1,724
Novartis Pharmaceuticals Corporation
$1,078
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,036
PFIZER INC.
$970
Actelion Pharmaceuticals US, Inc.
$757
Janssen Pharmaceuticals, Inc
$637
E.R. Squibb & Sons, L.L.C.
$583
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$513
Bayer HealthCare Pharmaceuticals Inc.
$447
Gilead Sciences, Inc.
$444
SANOFI-AVENTIS U.S. LLC
$328
Amarin Pharma Inc.
$311
Merck Sharp & Dohme LLC
$263
BIOTRONIK INC.
$233
Boston Scientific Corporation
$224
Edwards Lifesciences Corporation
$209
AstraZeneca Pharmaceuticals LP
$157
SCPHARMACEUTICALS INC.
$121
Impulse Dynamics (USA) Inc.
$100
Novo Nordisk Inc
$100
Relypsa, Inc.
$84
Medtronic Vascular, Inc.
$70
Bayer Healthcare Pharmaceuticals Inc.
$62
Merck Sharp & Dohme Corporation
$52
Alnylam Pharmaceuticals Inc.
$52
BOSTON SCIENTIFIC CORPORATION
$50
Vifor Pharma, Inc.
$41
Lexicon Pharmaceuticals, Inc.
$32
Biosense Webster, Inc.
$27
ABIOMED
$26
Kiniksa Pharmaceuticals, Ltd.
$26
Daiichi Sankyo Inc.
$25
Abbott Laboratories
$21
Akcea Therapeutics, Inc.
$18
Medtronic, Inc.
$18
Kestra Medical Technology Services, Inc.
$18
Astellas Pharma US Inc
$18
Amryt Pharma Holdings Ltd
$17
ARALEZ PHARMACEUTICALS US INC.
$15
Inogen, Inc.
$14
Regeneron Healthcare Solutions, Inc.
$12
Top 3 companies account for 35.1% of all-time payments
Associated products mentioned in payments ›
Adempas · Arcalyst · Assure WCD · Azure · BRILINTA · CAMZYOS · CHANTIX · Carto 3 System · Confirm Rx · Corlanor · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE (THV) · ELIQUIS · EMBLEM MRI S-ICD · ENTRESTO · Edwards SAPIEN 3 Transcatheter Heart Valve · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · Evera · FARXIGA · FUROSCIX · INJECTAFER · Impella · InogenOne · Inpefa · JARDIANCE · JUXTAPID · Kerendia · LEQVIO · LEXISCAN · LINQ II · LOKELMA · LOOP · LUX DX · LUX-Dx Insertable Cardiac Monitor · Letairis · LifeVest · MULTAQ · ONPATTRO · OPSUMIT · OPSUMIT MACITENTAN · OPTIMIZER · Optimizer · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · RESONATE · Repatha · Rybelsus · SAPIEN 3 Ultra RESILIA · TEGSEDI · UPTRAVI · VERQUVO · VIAGRA · VYNDAQEL · Vascepa · Veltassa · Verquvo · WATCHMAN Access System · WATCHMAN FLX · WINREVAIR · Wegovy · XARELTO · ZONTIVITY
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Cardiologists within 10 mi
94
Per 100K population
9.9
County median income
$71,175
Nearest hospital
UPSTATE NEW YORK VA HEALTHCARE SYSTEM (WESTERN NY VA HEALTHCARE SYSTEM)
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Gianfagna is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 19% of NY peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Gianfagna experienced with ekg interpretation and report?
Based on Medicare claims data, Dr. Gianfagna performed 719 ekg interpretation and report services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gianfagna receive payments from pharmaceutical companies?
Yes. Dr. Gianfagna received a total of $10,934 from 41 companies across 619 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gianfagna's costs compare to other cardiologists in Buffalo?
Dr. Gianfagna's average Medicare payment per service is $40. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gianfagna) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiologists in Buffalo
Browse cardiologists in Buffalo ranked by procedure volume and transparency data.
Highest volume
Top Cardiologists in NY
Cardiologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiologists in NY
Which NY cardiologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology